Teva seeks to launch generic Truvada, Gilead says

11/17/2008 | Reuters ·

Gilead Sciences said it was notified that Teva Pharmaceutical Industries filed for FDA approval to market a copy of Truvada, an HIV treatment combining Gilead's drugs Viread and Emtriva. Gilead, which has 45 days to file a patent-infringement suit against Teva, said 10 patents need to expire or be nullified before a generic version of Truvada can be launched.

View Full Article in:

Reuters ·

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA